Market
Significant Increase in ENHERTU® Prescriptions for HER2-low Breast Cancer by Q3 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Prescription data from IMS Health or similar pharmaceutical market analysis firms
Story
FDA Approves ENHERTU® for HER2-Low Breast Cancer, Showing 36% Risk Reduction and Hazard Ratio of 0.64
Jan 28, 2025, 12:04 AM
The U.S. Food and Drug Administration (FDA) has approved ENHERTU® (fam-trastuzumab deruxtecan-nxki) as the first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer. This approval is specifically for patients who have experienced disease progression following one or more endocrine therapies. Clinical data indicates that ENHERTU® demonstrated a 36% reduction in the risk of disease progression or death compared to chemotherapy, with a hazard ratio of 0.64 (95% confidence interval: 0.54-0.76; p<0.0001) in a trial involving chemotherapy-naïve patients with HER2-low or HER2-ultralow metastatic breast cancer. The approval marks a significant advancement in treatment options for this patient population, which previously had limited therapeutic alternatives.
View original story
Similar markets
More than 30% • 25%
10% to 20% • 25%
Less than 10% • 25%
20% to 30% • 25%
Yes • 50%
No • 50%
VIR-5818 higher ORR • 25%
Data not available • 25%
Same ORR • 25%
Enhertu higher ORR • 25%
Yes • 50%
No • 50%
40-60% • 25%
Less than 20% • 25%
20-40% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
More than 15% • 25%
10% to 15% • 25%
Less than 5% • 25%
5% to 10% • 25%
None • 25%
1 • 25%
3 or more • 25%
2 • 25%
None • 25%
Two • 25%
More than two • 25%
One • 25%
Roche • 25%
Pfizer • 25%
Novartis • 25%
Other • 25%
Enhertu (trastuzumab deruxtecan) • 25%
Other • 25%
Kisqali (ribociclib) • 25%
Verzenio (abemaciclib) • 25%